Faster global financial news!
Pharmaceuticals
-
China's Public Funds Q1-Q3 Performance Revealed: Semiconductors, Crude Oil, and Pharmaceuticals Lead the Pack
In the first three quarters of 2026, China's A-share public fund performance rankings show that driven by domestic semiconductor substitution and the AI hashrate wave, both actively managed equity fun
-
US-based Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials
US-based Bambusa Therapeutics Inc. filed for an initial public offering to help fund trials of its drugs to treat eczema and other inflammation disorders.
-
Sandoz CEO Warns: Donald Trump's Threat of 100%-200% Tariffs on Imported Generic Drugs Will Ultimately Be Borne by US Patients
Richard Saynor, CEO of Swiss pharmaceutical company Sandoz, stated in an interview with CNBC that no company would systematically continue to supply products at significant losses, thus manufacturers
-
Fosun International rebounds to stronger H1 profitability, shifts focus to pharmaceuticals, insurance, and tourism
The group's improved performance follows a clean-up of its property portfolio and was aided by the absence of heavy impairments that affected 2025 earnings. Chairman Guo Guangchang stated on Thursday
-
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
-
China's Public Funds Q1-Q3 Performance Revealed: Semiconductors, Crude Oil, and Pharmaceuticals Lead the Pack
In the first three quarters of 2026, China's A-share public fund performance rankings show that driven by domestic semiconductor substitution and the AI hashrate wave, both actively managed equity fun
-
US-based Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials
US-based Bambusa Therapeutics Inc. filed for an initial public offering to help fund trials of its drugs to treat eczema and other inflammation disorders.
-
Sandoz CEO Warns: Donald Trump's Threat of 100%-200% Tariffs on Imported Generic Drugs Will Ultimately Be Borne by US Patients
Richard Saynor, CEO of Swiss pharmaceutical company Sandoz, stated in an interview with CNBC that no company would systematically continue to supply products at significant losses, thus manufacturers
-
Fosun International rebounds to stronger H1 profitability, shifts focus to pharmaceuticals, insurance, and tourism
The group's improved performance follows a clean-up of its property portfolio and was aided by the absence of heavy impairments that affected 2025 earnings. Chairman Guo Guangchang stated on Thursday
-
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
- No data
Pharmaceuticals
24H Trending
-
1
Regulatory Landscape of Virtual Currencies in Mainland China and Risks Associated with Using Overseas Trading Platforms
-
2
SKR Tokenomics Analysis: The Core Driver of the Solana Mobile Ecosystem
-
3
According to Bloomberg Markets: Large asset managers are deleveraging in the U.S. Treasury futures market, triggered by forced selling as cash yields approach multi-year highs.
-
4
Wall Street's Rate Shock Spreads Beneath AI-Fueled Market Rally, Driven by High Oil Prices and Borrowing Costs
-
5
iPhone Vulnerabilities Continue to Threaten Crypto Users, Older iOS Devices Remain at Risk
-
6
TypeSafe AI, the maker of the non-text AI model Jev, reached a valuation of $7.5 billion just weeks after its launch, with a16z leading an $870 million funding round.
-
7
Hungary Needs Significant Deficit Cut For Euro Path, Magyar Says
-
8
Base Network: Coinbase's Layer 2 Solution and Its Ecosystem Development Status
-
9
NEMO Token: Multi-Entity Identification and Trading Status
-
10
Neo (Antcoin) In-depth Analysis: The Technical Evolution and Ecosystem Layout of "China's Ethereum"
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
